×
About 2,123 results

ALLMedicine™ Neuromuscular Diseases Center

Research & Reviews  689 results

Data Collection of Standard Care of Patients in the EMG Section
https://clinicaltrials.gov/ct2/show/NCT05041387

Aug 5th, 2022 - PROTOCOL SUMMARY Title: Data Collection for Standard Care of Patients in the EMG Section Study Description: This protocol is designed to provide a repository of information for future hypothesis generation. We will be evaluating patients with neur...

Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
https://clinicaltrials.gov/ct2/show/NCT02892890

Jul 29th, 2022 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an acquired neuropathy characterized by an inflammatory multifocal segmental demyelination. Due to the clinical heterogeneity of this condition and the lack of specific marker tha...

Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
https://clinicaltrials.gov/ct2/show/NCT03645031

Jul 26th, 2022 - Most ALS patients survive less than 5 years after diagnosis, and the main cause of death is respiratory failure. The investigators are interested in the therapeutic potential of acute intermittent hypoxia (AIH) for individuals with neuromuscular d...

Cardiac involvement in two rare neuromuscular diseases: LAMA2-related muscular dystroph...
https://doi.org/10.1016/j.nmd.2022.06.004
Neuromuscular Disorders : NMD; Bouman K, Gubbels M et. al.

Jul 23rd, 2022 - LAMA2-related muscular dystrophy (LAMA2-MD) and SELENON(SEPN1)-related myopathy (SELENON-RM) are rare neuromuscular diseases caused by mutations in the LAMA2 and SELENON (SEPN1) gene, respectively. Systematic reviews on cardiac features in both ne...

Neuromuscular diseases and their cardiac manifestations under the spectrum of cardiovas...
https://doi.org/10.1007/s10741-022-10260-8
Heart Failure Reviews; Alexandridis GM, Pagourelias ED et. al.

Jul 21st, 2022 - Neuromuscular diseases (NMDs) include a broad spectrum of disorders that affect motor unit in every possible site, extending from the cell body of peripheral nerves to the muscle. The different lesion sites make this group of inherited disorders d...

see more →

Guidelines  1 results

Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific ...
https://doi.org/10.1161/CIR.0000000000000526
Circulation Feingold B, Mahle WT et. al.

Aug 26th, 2017 - For many neuromuscular diseases (NMDs), cardiac disease represents a major cause of morbidity and mortality. The management of cardiac disease in NMDs is made challenging by the broad clinical heterogeneity that exists among many NMDs and by limit...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  127 results

Data Collection of Standard Care of Patients in the EMG Section
https://clinicaltrials.gov/ct2/show/NCT05041387

Aug 5th, 2022 - PROTOCOL SUMMARY Title: Data Collection for Standard Care of Patients in the EMG Section Study Description: This protocol is designed to provide a repository of information for future hypothesis generation. We will be evaluating patients with neur...

Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
https://clinicaltrials.gov/ct2/show/NCT02892890

Jul 29th, 2022 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an acquired neuropathy characterized by an inflammatory multifocal segmental demyelination. Due to the clinical heterogeneity of this condition and the lack of specific marker tha...

Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
https://clinicaltrials.gov/ct2/show/NCT03645031

Jul 26th, 2022 - Most ALS patients survive less than 5 years after diagnosis, and the main cause of death is respiratory failure. The investigators are interested in the therapeutic potential of acute intermittent hypoxia (AIH) for individuals with neuromuscular d...

S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
https://clinicaltrials.gov/ct2/show/NCT04141670

Jul 19th, 2022 - RYR1- related myopathy comprises a group of rare neuromuscular diseases. Affected individuals generally present with delayed motor milestones, muscle weakness, impaired ambulation, and, in severe cases, scoliosis, ophthalmoplegia, and respiratory ...

The Bridges Self-management Programme for People With Neuromuscular Diseases
https://clinicaltrials.gov/ct2/show/NCT05460156

Jul 15th, 2022 - Objectives To explore the feasibility of delivering and evaluating NM Bridges through a single, specialist service: Feasibility of evaluation To examine the acceptability and performance of candidate outcome measures that consider the priorities, ...

see more →

News  27 results

New Genetic Test Finds Hidden Neurological Diseases
https://www.medscape.com/viewarticle/970530

Mar 18th, 2022 - Neurological disorders can be some of the most difficult conditions to diagnose. Symptoms are similar for multiple different conditions and sometimes they vary a lot between patients, which can make diagnosis hard to pinpoint. Delays means that in...

Sleep-disordered breathing in neuromuscular disease: Early noninvasive ventilation needed
https://www.mdedge.com/chestphysician/article/242654/sleep-medicine/sleep-disordered-breathing-neuromuscular-disease-early
Christine Kilgore, MDedge News

Jul 8th, 2021 - Sleep-disordered breathing is common in patients with neuromuscular disease and is increasingly addressed with noninvasive ventilation, but its patterns go beyond obstructive sleep apnea (OSA) and include hypoventilation, hypoxemia, central sleep.

Dalantercept Falls Short in Phase II RCC Trial
https://www.onclive.com/view/dalantercept-falls-short-in-phase-ii-rcc-trial

Nov 13th, 2020 - The combination of dalantercept plus axitinib (Inlyta) failed to significantly improve progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to results from the phase II DART trial. ...

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals
https://www.reuters.com/article/us-exonics-therapeutics-m-a-vertex-pharm/vertex-pharmaceuticals-expands-into-duchenne-gene-therapy-with-new-deals-idUSKCN1T72YK

Jun 6th, 2019 - (Reuters) - Vertex Pharmaceuticals Inc said here on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million. Exonics Therapeutics develops gene edi...

see more →

Patient Education  4 results see all →